Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates in prostate carcinoma

S Adami1

  • 1Department of Rheumatology, Ospedale di Valeggio, University of Verona, Italy.

Cancer
|November 15, 1997
PubMed
Summary
This summary is machine-generated.

Bisphosphonates effectively manage bone pain from prostate cancer metastases. Intravenous and oral bisphosphonates, like clodronate and alendronate, offer significant pain relief and improve quality of life for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution of European Medicines Agency drug approval: the adaptive licensing.

European journal of hospital pharmacy : science and practice·2019
Same author

The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Guidelines for the diagnosis, prevention and management of osteoporosis.

Reumatismo·2016
Same author

Teriparatide and denosumab combination therapy and skeletal metabolism.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same author

Budget Impact Analysis Of Sofosbuvir For The Treatment Of Hepatitis C In The Veneto Region, Italy.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same journal

Bendamustine in indolent lymphoma: Letting the dust settle down.

Cancer·2026
Same journal

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Cancer·2026
Same journal

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

Cancer·2026
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Skeletal Biology

Background:

  • Advanced prostate carcinoma frequently causes painful skeletal metastases.
  • Osteoclastic activation precedes osteoblastic bone formation in metastases, contributing to bone pain.
  • Bisphosphonates inhibit osteoclastic bone resorption, making them a rationale for treating bone pain.

Purpose of the Study:

  • To evaluate the efficacy of bisphosphonates in managing bone pain associated with skeletal metastases in prostate carcinoma.
  • To compare the effectiveness of intravenous and oral administration of bisphosphonates.
  • To assess the role of bisphosphonates in preventing skeletal morbidity.

Main Methods:

  • Investigated the bisphosphonate clodronate, administered intravenously (300 mg/day) and orally (1600-3200 mg/day).

Related Experiment Videos

  • Evaluated alendronate given intravenously (5 mg) and orally (40 mg/day).
  • Observed pain relief, onset of action, and duration of effect.

    • Main Results:

    • Intravenous clodronate provided appreciable bone pain relief within 3 days, with rare unresponsive patients.
    • Oral clodronate was effective but required higher doses and had a delayed onset.
    • Alendronate showed comparable or superior efficacy to clodronate, with oral administration being effective in non-bedridden patients.
    • Potential for bisphosphonates to aggravate osteomalacia and cause hypocalcemia, necessitating calcium supplementation.

    Conclusions:

    • Bisphosphonate administration, particularly at high doses, is a cost-effective palliative treatment for prostate cancer bone metastases.
    • Bisphosphonates can maintain patients free of bone pain, improving quality of life.
    • Further studies are warranted to explore lower doses for preventing skeletal morbidity in earlier stages of bone disease.